Humacyte, Inc.
HUMA
Positions held
Your positionsHUMA isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $124.20M | Enterprise value | $111.18M | Trailing P/E | — | Forward P/E | -1.81 |
| PEG | — | Price / book | 3.96 | Beta | 2.44 | Dividend yield | 0.00% |
| Revenue growth | 34.9% | Earnings growth | — | Gross margin | 0.0% | Operating margin | -66.5% |
| Profit margin | 0.0% | ROE | -5.5% | ROA | -49.9% | Debt / equity | 2.14 |
| Current ratio | 6.21 | Free cash flow | -$58.39M | Analyst recommendation | buy | Mean target | $1.63 |
| 52w high | $1.90 | 52w low | $0.44 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.4M | $0.5M | $0.5M | $0.8M | $0.3M | — |
| Op margin | -6649.3% | -5845.5% | -6603.0% | -3239.0% | -9876.1% | — |
| Net income | -$36.8M | -$17.6M | -$24.8M | -$17.5M | -$37.7M | — |
| Gross margin | -203.2% | -311.7% | -1844.8% | 65.5% | 29.2% | — |
| Gross profit | -$0.8M | -$1.5M | -$8.6M | $0.5M | $0.1M | — |
| Operating income | -$27.0M | -$28.9M | -$30.8M | -$24.4M | -$29.7M | — |
- Revenue -18% vs prior quarter ($0.4M vs $0.5M).
- Gross margin -203.2% (was -311.7% prior quarter).
- Operating margin compressed to -6649.3%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | -5306.0% | — | — | — | — |
| Net income | -$40.8M | -$149M | -$111M | -$12.0M | — |
| Gross margin | -376.1% | — | — | — | — |
| Gross profit | -$7.7M | $0.0M | — | — | — |
| Operating income | -$108M | -$114M | -$100M | -$84.6M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Humacyte (HUMA) Stock Fair Value Moves Lower After Analyst Target Cuts
2026-10-07 · Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls
2026-10-06 · Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade
2026-10-01 · Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note
2026-09-28 · Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
2026-09-25 · Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
2026-09-18 · Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know
2026-09-17 · Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic?
2026-09-10 · Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-09 · Humacyte Gets US FDA Clearance to Extend Symvess Shelf Life to 36 Months
2026-09-09 · Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months
2026-08-24 · Humacyte Plans FDA Filing for Acellular Tissue Engineered Vessel in Dialysis Access
Price (daily)
Full chart · RSI · MACD · patterns